Suppr超能文献

临床淋巴结阴性的肢体默克尔细胞癌患者:识别和治疗有微小淋巴结转移患者的重要性。

Patients with clinically node negative extremity Merkel cell carcinoma: The importance of identifying and treating patients with microscopic nodal metastases.

作者信息

Veness Michael, Howle Julie

机构信息

Department of Radiation Oncology, University of Sydney, Westmead Hospital, Sydney, New South Wales, Australia.

出版信息

Australas J Dermatol. 2010 Nov;51(4):274-8. doi: 10.1111/j.1440-0960.2010.00702.x. Epub 2010 Oct 13.

Abstract

OBJECTIVES

To review the management of patients with Merkel cell carcinoma (MCC) of the distal arm or leg.

METHODS

The files of 27 patients with clinically node-negative extremity-located MCC treated between 1993 and 2007 at Westmead Hospital, Sydney, were reviewed.

RESULTS

The median age was 79 (range 48-91 years); there were 16 women and 11 men. The median follow up was 36 months. Eighteen patients had a below knee primary and nine had a below elbow primary. None had previous treatment of draining nodes. Most (26/27) underwent excision and 10 of the 27 received adjuvant local radiotherapy. The median lesion size was 19 mm (range 10-30 mm). In total 55% relapsed with most occurrences in the ipsilateral nodes of the axilla or groin. Median time to relapse was 5.5 months. Overall survival at two and five years was 68% and 57%, respectively.

CONCLUSIONS

Patients with extremity MCC experience a high rate of nodal relapse. Recently published evidence supports a survival benefit to identifying patients with microscopic nodal metastases. As en bloc primary and nodal treatment is not possible, and elective nodal treatment is likely to over-treat many patients, sentinel lymph node biopsy is a useful adjunct to current investigations and should be recommended.

摘要

目的

回顾远端手臂或腿部默克尔细胞癌(MCC)患者的治疗情况。

方法

回顾了1993年至2007年间在悉尼韦斯特米德医院接受治疗的27例临床淋巴结阴性的肢体MCC患者的病历。

结果

中位年龄为79岁(范围48 - 91岁);女性16例,男性11例。中位随访时间为36个月。18例患者原发灶位于膝下,9例位于肘下。均未对引流淋巴结进行过先前治疗。大多数患者(26/27)接受了切除手术,27例中有10例接受了辅助局部放疗。病变中位大小为19毫米(范围10 - 30毫米)。共有55%的患者复发,大多数复发发生在腋窝或腹股沟的同侧淋巴结。中位复发时间为5.5个月。两年和五年的总生存率分别为68%和57%。

结论

肢体MCC患者淋巴结复发率高。最近发表的证据支持识别有微小淋巴结转移的患者可带来生存获益。由于无法进行原发灶和淋巴结的整块切除,且选择性淋巴结治疗可能会过度治疗许多患者,前哨淋巴结活检是当前检查的有用辅助手段,应予以推荐。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验